,7,9 Interestingly, the levels of anti-BP180 immunoglobulin G have been linked with improved therapy response and overall survival, as well as a higher propensity of developing ICI-BP during anti-PD-1/PD-L1 treatment in patients with non-small cell lung cancer.9 This evidence concerns the gene COL17A1 and non-small cell lung carcinoma.